Pharma update: Bullish for 4Q24
It has been a long time since I wrote on this website. Things are getting busy! A lot of things happened in biotech/pharma land - however, for ALL THAT NOISE,…
Key beneficiaries of the latest drug pricing reform as it currently stands – hint: rare disease, large/complex drugs
With mid-term election just around the corner, politicians are focusing on key items that they can talk about as we ramp into voting ballot. One of the popular items that…